Zhejiang Orient Gene Biotech Co Ltd (688298) - Net Assets
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has net assets worth CN¥6.49 Billion CNY (≈ $950.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.51 Billion ≈ $1.10 Billion USD) and total liabilities (CN¥1.01 Billion ≈ $148.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Zhejiang Orient Gene Biotech Co Ltd (688298) tangible net worth to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.49 Billion |
| % of Total Assets | 86.48% |
| Annual Growth Rate | 69.71% |
| 5-Year Change | 177.04% |
| 10-Year Change | N/A |
| Growth Volatility | 277.82 |
Zhejiang Orient Gene Biotech Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See 688298 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual net assets of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. For live valuation and market cap data, see market value of Zhejiang Orient Gene Biotech Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.79 Billion ≈ $993.80 Million |
-10.04% |
| 2023-12-31 | CN¥7.55 Billion ≈ $1.10 Billion |
-9.29% |
| 2022-12-31 | CN¥8.32 Billion ≈ $1.22 Billion |
+20.82% |
| 2021-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
+181.01% |
| 2020-12-31 | CN¥2.45 Billion ≈ $358.72 Million |
+864.64% |
| 2019-12-31 | CN¥254.13 Million ≈ $37.19 Million |
+22.16% |
| 2018-12-31 | CN¥208.03 Million ≈ $30.44 Million |
+50.62% |
| 2017-12-31 | CN¥138.12 Million ≈ $20.21 Million |
+39.91% |
| 2016-12-31 | CN¥98.72 Million ≈ $14.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Orient Gene Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 619606382949.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥6.18 Billion | 93.06% |
| Common Stock | CN¥201.60 Million | 3.03% |
| Other Comprehensive Income | CN¥143.20 Million | 2.15% |
| Other Components | CN¥116.64 Million | 1.76% |
| Total Equity | CN¥6.65 Billion | 100.00% |
Zhejiang Orient Gene Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pareto Bank ASA
OL:PARB
|
$568.00 Million |
|
China Railway Harbin Group of Technology Corp. A
SHG:688459
|
$568.23 Million |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
$568.26 Million |
|
FinVolution Group
F:PP3
|
$568.31 Million |
|
Canadian Banc Corp
TO:BK
|
$567.57 Million |
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
$567.57 Million |
|
Beijing StarNeto Technology Co Ltd
SHE:002829
|
$567.13 Million |
|
Indointernet Tbk PT
JK:EDGE
|
$567.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Orient Gene Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,436,071,401 to 6,645,091,305, a change of -790,980,096 (-10.6%).
- Net loss of 529,022,760 reduced equity.
- Dividend payments of 16,631,227 reduced retained earnings.
- Share repurchases of 276,947,754 reduced equity.
- Other comprehensive income increased equity by 143,198,098.
- Other factors decreased equity by 111,576,453.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-529.02 Million | -7.96% |
| Dividends Paid | CN¥16.63 Million | -0.25% |
| Share Repurchases | CN¥276.95 Million | -4.17% |
| Other Comprehensive Income | CN¥143.20 Million | +2.15% |
| Other Changes | CN¥-111.58 Million | -1.68% |
| Total Change | CN¥- | -10.64% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Orient Gene Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.57x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 17.57x to 0.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.09 | CN¥19.24 | x |
| 2017-12-31 | CN¥0.88 | CN¥19.24 | x |
| 2018-12-31 | CN¥1.34 | CN¥19.24 | x |
| 2019-12-31 | CN¥1.66 | CN¥19.24 | x |
| 2020-12-31 | CN¥12.40 | CN¥19.24 | x |
| 2021-12-31 | CN¥47.62 | CN¥19.24 | x |
| 2022-12-31 | CN¥48.60 | CN¥19.24 | x |
| 2023-12-31 | CN¥36.85 | CN¥19.24 | x |
| 2024-12-31 | CN¥33.79 | CN¥19.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Orient Gene Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -63.90%
- • Asset Turnover: 0.10x
- • Equity Multiplier: 1.22x
- Recent ROE (-7.96%) is below the historical average (30.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 36.09% | 19.55% | 0.76x | 2.44x | CN¥25.76 Million |
| 2017 | 24.99% | 14.88% | 0.86x | 1.94x | CN¥20.01 Million |
| 2018 | 32.52% | 22.87% | 0.85x | 1.68x | CN¥45.27 Million |
| 2019 | 32.62% | 22.35% | 1.02x | 1.44x | CN¥56.93 Million |
| 2020 | 68.57% | 51.37% | 0.91x | 1.46x | CN¥1.43 Billion |
| 2021 | 71.75% | 48.38% | 1.13x | 1.31x | CN¥4.23 Billion |
| 2022 | 25.33% | 23.58% | 0.82x | 1.31x | CN¥1.25 Billion |
| 2023 | -5.35% | -48.48% | 0.09x | 1.21x | CN¥-1.14 Billion |
| 2024 | -7.96% | -63.90% | 0.10x | 1.22x | CN¥-1.19 Billion |
Industry Comparison
This section compares Zhejiang Orient Gene Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Orient Gene Biotech Co Ltd (688298) | CN¥6.49 Billion | 36.09% | 0.16x | $567.59 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more